From Wikipedia, the free encyclopedia
Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker.[1][2] It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication.[3][4] Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned,[1] and the drug was ultimately never marketed.
References
|
---|
Calcium | VDCCsTooltip Voltage-dependent calcium channels | |
---|
|
---|
Potassium | VGKCsTooltip Voltage-gated potassium channels | |
---|
IRKsTooltip Inwardly rectifying potassium channel | |
---|
KCaTooltip Calcium-activated potassium channel | |
---|
K2PsTooltip Tandem pore domain potassium channel | |
---|
|
---|
Sodium | VGSCsTooltip Voltage-gated sodium channels | |
---|
ENaCTooltip Epithelial sodium channel | |
---|
ASICsTooltip Acid-sensing ion channel | |
---|
|
---|
Chloride | CaCCsTooltip Calcium-activated chloride channel | |
---|
CFTRTooltip Cystic fibrosis transmembrane conductance regulator | |
---|
Unsorted | |
---|
|
---|
Others | TRPsTooltip Transient receptor potential channels | |
---|
LGICsTooltip Ligand gated ion channels | |
---|
|
---|
|
|
---|
AMPARTooltip α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor | |
---|
KARTooltip Kainate receptor | |
---|
NMDARTooltip N-Methyl-D-aspartate receptor | |
---|
|